Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Colorectal Cancer
How would you manage anastomotic site recurrence of colon cancer 3 years after resection of a T3N0 tumor without high-risk features?
Answer from: Medical Oncologist at Community Practice
I will do metastatic work up. If negative:- FOLFOX.
Sign in or Register to read more
12554
Related Questions
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?
How do you approach an isolated metastasis to left supraclavicular node in rectal cancer treated with TNT with FOLFOX regimen followed by long course radiation?
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
For a patient with metastatic colon cancer which is MSI-H/dMMR and BRAF V600E+, what would be your preferred first line treatment?
Would you do adjuvant chemo in patient pT3N0 colon with intussusception on imaging and partial obstruction on colonoscopy?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?